• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾衰竭时药物的体内代谢降低。

Decreased in vivo metabolism of drugs in chronic renal failure.

作者信息

Leblond F A, Giroux L, Villeneuve J P, Pichette V

机构信息

Service de Néphrologie et Centre de Recherche Guy-Bernier, Hopital Maisonneuve-Rosemont, Faculté de Médecine, Université de Montréal, Québec, Canada.

出版信息

Drug Metab Dispos. 2000 Nov;28(11):1317-20.

PMID:11038159
Abstract

Chronic renal failure (CRF) is associated with a decrease in renal excretion of drugs, but its effects on the liver metabolism of xenobiotics are poorly defined. The objectives of this study were to determine the effects of CRF on hepatic cytochrome P450 (CYP450) and its repercussions on in vivo hepatic metabolism of drugs. Two groups of rats were studied: control paired-fed and CRF. CRF was induced by subtotal nephrectomy. Total CYP450 activity and protein expression of several CYP450 isoforms (CYP1A2, CYP2C11, CYP3A1, CYP3A2) were assessed in liver microsomes. In vivo cytochrome P450 activity was evaluated with breath tests using substrates for different isoenzymes: caffeine (CYP1A2), aminopyrine (CYP2C11), and erythromycin (CYP3A2). Creatinine clearance was reduced by 60% (P <. 01) in rats with CRF. Compared with control paired-fed rats, total CYP450 activity was reduced by 40% in rats with CRF. Protein expression of CYP2C11, CYP3A1, and CYP3A2 was considerably reduced (more than 45%, P <.001) in rats with CRF, whereas the levels of CYP1A2 were unchanged. In rats with CRF, there was a 35% reduction in the aminopyrine (CYP2C11) and the erythromycin (CYP3A2) breath tests compared with control animals (P <.001). The caffeine (CYP1A2) breath tests remained comparable to controls. Creatinine clearance correlated with the aminopyrine and erythromycin breath tests (r(2) = 0.73 and r(2) = 0.81, respectively, P <.001). In conclusion, CRF is associated with a decrease in total liver CYP450 activity in rats (mainly in CYP2C11, CYP3A1, and CYP3A2), which leads to a significant decrease in the metabolism of drugs.

摘要

慢性肾衰竭(CRF)与药物经肾排泄减少有关,但其对外源性物质肝脏代谢的影响尚不明确。本研究的目的是确定CRF对肝脏细胞色素P450(CYP450)的影响及其对药物体内肝脏代谢的影响。研究了两组大鼠:对照配对喂养组和CRF组。通过次全肾切除术诱导CRF。在肝微粒体中评估总CYP450活性和几种CYP450同工酶(CYP1A2、CYP2C11、CYP3A1、CYP3A2)的蛋白表达。使用不同同工酶的底物通过呼气试验评估体内细胞色素P450活性:咖啡因(CYP1A2)、氨基比林(CYP2C11)和红霉素(CYP3A2)。CRF大鼠的肌酐清除率降低了60%(P<.01)。与对照配对喂养的大鼠相比,CRF大鼠的总CYP450活性降低了40%。CRF大鼠中CYP2C11、CYP3A1和CYP3A2的蛋白表达显著降低(超过45%,P<.001),而CYP1A2的水平未改变。与对照动物相比,CRF大鼠的氨基比林(CYP2C11)和红霉素(CYP3A2)呼气试验降低了35%(P<.001)。咖啡因(CYP1A2)呼气试验与对照组相当。肌酐清除率与氨基比林和红霉素呼气试验相关(r2分别为0.73和0.81,P<.001)。总之,CRF与大鼠肝脏总CYP450活性降低有关(主要是CYP2C11、CYP3A1和CYP3A2),这导致药物代谢显著降低。

相似文献

1
Decreased in vivo metabolism of drugs in chronic renal failure.慢性肾衰竭时药物的体内代谢降低。
Drug Metab Dispos. 2000 Nov;28(11):1317-20.
2
Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure.慢性肾衰竭小鼠模型中肝药物代谢酶的下调。
Drug Metab Dispos. 2010 Mar;38(3):357-60. doi: 10.1124/dmd.109.029991. Epub 2009 Dec 9.
3
Downregulation of hepatic cytochrome P450 in chronic renal failure.慢性肾衰竭时肝细胞色素P450的下调
J Am Soc Nephrol. 2001 Feb;12(2):326-332. doi: 10.1681/ASN.V122326.
4
Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis.肝硬化两种实验模型中细胞色素P450同工酶的差异改变
Can J Physiol Pharmacol. 2000 Nov;78(11):912-9.
5
Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats.慢性肾衰竭对大鼠肾脏药物转运体和细胞色素 P450 的影响。
Drug Metab Dispos. 2011 Aug;39(8):1363-9. doi: 10.1124/dmd.111.039115. Epub 2011 Apr 27.
6
Downregulation of intestinal cytochrome p450 in chronic renal failure.慢性肾衰竭时肠道细胞色素P450的下调
J Am Soc Nephrol. 2002 Jun;13(6):1579-85. doi: 10.1097/01.asn.0000017575.50319.77.
7
Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators.慢性肾衰竭时肝脏细胞色素P450的下调:尿毒症介质的作用
Br J Pharmacol. 2002 Dec;137(7):1039-46. doi: 10.1038/sj.bjp.0704951.
8
Down-regulation of intestinal drug transporters in chronic renal failure in rats.大鼠慢性肾衰竭时肠道药物转运体的下调
J Pharmacol Exp Ther. 2007 Mar;320(3):978-85. doi: 10.1124/jpet.106.112631. Epub 2006 Nov 29.
9
Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure.甲状旁腺激素在慢性肾衰竭时肝脏细胞色素P450下调中的作用。
J Am Soc Nephrol. 2006 Nov;17(11):3041-8. doi: 10.1681/ASN.2006010035. Epub 2006 Oct 4.
10
Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: the pathway and concentration dependence.大鼠细胞色素P450同工型对咖啡因代谢的相对贡献:途径及浓度依赖性
Biochem Pharmacol. 2008 Apr 1;75(7):1538-49. doi: 10.1016/j.bcp.2007.12.017. Epub 2008 Jan 5.

引用本文的文献

1
The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis.多替拉韦+利匹韦林固定剂量复方制剂在血液透析中的稳态药代动力学
AIDS. 2025 Mar 15;39(4):356-361. doi: 10.1097/QAD.0000000000004071. Epub 2024 Nov 22.
2
Simultaneous determination of the combined and free concentrations of atorvastatin and its major metabolite and based on ultrafiltration coupled with UPLC-MS/MS method: an application in a protein binding rate and metabolism ability study in uremic hemodialysis patients.基于超滤结合超高效液相色谱-串联质谱法同时测定阿托伐他汀及其主要代谢物的结合型和游离型浓度:在尿毒症血液透析患者蛋白结合率及代谢能力研究中的应用
Front Cardiovasc Med. 2024 Oct 24;11:1461181. doi: 10.3389/fcvm.2024.1461181. eCollection 2024.
3
Prospective Trial on the Pharmacokinetics of Clopidogrel in Hemodialysis Patients.氯吡格雷在血液透析患者中药代动力学的前瞻性试验
Kidney Int Rep. 2024 Jul 31;9(10):2970-2980. doi: 10.1016/j.ekir.2024.07.029. eCollection 2024 Oct.
4
The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight.口服抗凝时代的肾功能损害。病理生理学的见解。
Cardiovasc Drugs Ther. 2021 Jun;35(3):505-519. doi: 10.1007/s10557-020-07004-x.
5
Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease.实验性肾病中黄素单加氧酶介导的三甲胺 N-氧化物形成的代谢激活。
Sci Rep. 2019 Nov 4;9(1):15901. doi: 10.1038/s41598-019-52032-9.
6
Pharmacokinetics in children with chronic kidney disease.儿童慢性肾脏病的药代动力学。
Pediatr Nephrol. 2020 Jul;35(7):1153-1172. doi: 10.1007/s00467-019-04304-9. Epub 2019 Aug 2.
7
Pharmacokinetic study of imrecoxib in patients with renal insufficiency.肾功能不全患者伊米昔布的药代动力学研究。
Eur J Clin Pharmacol. 2019 Oct;75(10):1355-1360. doi: 10.1007/s00228-019-02698-x. Epub 2019 Jun 27.
8
The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.慢性肾脏病对雄性 Wistar 大鼠 CYP2B 表达和活性的影响。
Pharmacol Res Perspect. 2019 Apr 26;7(3):e00475. doi: 10.1002/prp2.475. eCollection 2019 Jun.
9
Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease.芳香烃受体在慢性肾脏病期间药物清除改变中的新兴作用。
Toxins (Basel). 2019 Apr 7;11(4):209. doi: 10.3390/toxins11040209.
10
Recovery of OATP1B Activity after Living Kidney Transplantation in Patients with End-Stage Renal Disease.终末期肾病患者活体肾移植后 OATP1B 活性的恢复。
Pharm Res. 2019 Feb 26;36(4):59. doi: 10.1007/s11095-019-2593-8.